{"entity":{"id":"nct06968585","kind":"trial","name":"A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy","aka":[],"tldr":"A phase 3 trial testing A166 in HER2-positive breast cancer, active and no longer recruiting.","summary":"A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy is a phase 3 interventional study registered as NCT06968585, led by Sichuan Kelun-Biotech Biopharmaceutical, and active but no longer recruiting on the registry. Official title: A Phase III,Multicenter,Randomised,Open-Label,Active-Controlled Trial of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy. Planned enrolment is 365 participants (actual). The study started in 2023-07-18 and primary completion is expected in 2026-11-30. No results have been posted on ClinicalTrials.gov.","status":"active","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT06968585","url":"https://clinicaltrials.gov/study/NCT06968585"}],"tags":["ctgov-ingest"],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["a166"],"companies":["kelun-biotech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct06968585-j-clin-oncol-2026"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06968585","phase":"3","setting":"A Phase III,Multicenter,Randomized,Open-Label,Active-Controlled Trial of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical","started":"2023-07-18","startedType":"actual","enrolled":365,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06968585/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"drug":[{"id":"a166","kind":"drug","name":"A166","route":"/drugs/a166/"}],"company":[{"id":"kelun-biotech","kind":"company","name":"Sichuan Kelun-Biotech","route":"/companies/kelun-biotech/"}],"paper":[{"id":"paper-nct06968585-j-clin-oncol-2026","kind":"paper","name":"Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial","route":"/key-papers/paper-nct06968585-j-clin-oncol-2026/"}]}}